Altar Rock LLC’s Charles River Laboratories CRL Stock Holding History

Altar Rock LLC’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,144	Closed	-$228K	–	155
2025 Q4	$228K	Buy	+1,144	New	+$208K	0.27%	99

Other funds holding CRL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Altar Rock LLC's CRL Position: Q1 2026 in Review

Altar Rock LLC sold out of Charles River Laboratories (CRL) in Q1 2026, closing a stake of 1,144 shares — an estimated $228K sold.

Altar Rock LLC first reported a position in CRL in Q4 2025 and held it in 1 quarter. The position peaked at $228K in Q4 2025. 560 funds tracked by Wall St. Rank hold CRL as of Q1 2026.

Altar Rock LLC reported no remaining Charles River Laboratories position as of Q1 2026 after selling out during the quarter.
Altar Rock LLC sold 1,144 Charles River Laboratories shares in Q1 2026, an estimated $228K.
Altar Rock LLC first reported a position in Charles River Laboratories in Q4 2025 and held it in 1 quarter.
Altar Rock LLC's Charles River Laboratories position peaked at $228K in Q4 2025.
560 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.

Based on Altar Rock LLC's 13F filing for Q1 2026, filed 21 Sep 2026.